SECURITIES AND EXCHANGE COMMISSIONSEC FORM 17-C

CURRENT REPORT UNDER SECTION 17
OF THE SECURITIES REGULATION CODE
AND SRC RULE 17.2(c) THEREUNDER

1. Date of Report (Date of earliest event reported)

Mar 19, 2024

2. SEC Identification Number

148022

3. BIR Tax Identification No.

000-288-655-000

4. Exact name of issuer as specified in its charter

Euro-Med Laboratories Phil., Inc.

5. Province, country or other jurisdiction of incorporation

Metro Manila

6. Industry Classification Code(SEC Use Only)

7. Address of principal office

PPL Building, United Nations Avenue corner San Marcelino St., Manila Postal Code 1007

8. Issuer's telephone number, including area code

00-63-2-85240091 to 98

9. Former name or former address, if changed since last report

N/A

10. Securities registered pursuant to Sections 8 and 12 of the SRC or Sections 4 and 8 of the RSA

Title of Each Class	Number of Shares of Common Stock Outstanding and Amount of Debt Outstanding
common shares	4,112,140,540

11. Indicate the item numbers reported herein

Item 9 : Other Events

The Exchange does not warrant and holds no responsibility for the veracity of the facts and representations contained in all corporate disclosures, including financial reports. All data contained herein are prepared and submitted by the disclosing party to the Exchange, and are disseminated solely for purposes of information. Any questions on the data contained herein should be addressed directly to the Corporate Information Officer of the disclosing party.

Euro-Med Laboratories Phil., Inc.EURO

PSE Disclosure Form 4-30 - Material Information/Transactions References: SRC Rule 17 (SEC Form 17-C) and
Sections 4.1 and 4.4 of the Revised Disclosure Rules

Subject of the Disclosure
Nominees for Election as Members of the Board of Directors 2024-2025
Background/Description of the Disclosure
Please be advised that our Board of Directors, at its regular meeting today, March 19, 2024 at 3:30p.m. in which a quorum was present and acted throughout, unanimously approved the following list of nominees that has been approved by the Nomination Committee for election as members of the Board of Directors 2024-2025, to wit : Dr. William G. Padolina (Independent Director) Mr. Edwin D. Feist (Independent Director) Dr. Esperanza I. Cabral (Independent Director) Mr. Basilio C. Yap Mrs. Georgiana S. Evidente Dr. Johnny C. Yap Dr. Evangeline V. Baviera Mr. Benjamin C. Yap Dr. Enrique Y. Yap, Jr. Mr. Anthony Joseph Y. Gaw The above-mentioned nominees have been determined to possess all the qualifications and none of the disqualifications of a director. Mr. Edwin D. Feist, Dr. William G. Padolina and Mme. Esperanza I. Cabral. M.D. are nominated as independent directors. Dr. Padolina and Mr. Feist have both served the maximum cumulative term of nine years pursuant to SEC Memorandum Circular No. 4, Series of 2017. The Board of Directors resolved to approve their re-nomination due to their invaluable contribution to the attainment of the Company’s success during their tenure as Independent Directors. Further meritorious justification for their re-nomination will be provided in the Company’s Information Statement. The election of said directors will be submitted for approval of the shareholders in the Annual Shareholders’ Meeting of the Corporation.
Other Relevant Information
N/A